Evidence map›Paper›PMID 38494658›Full record

ArticleJournal of psychopharmacology (Oxford, England)2024

Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.

Adam Jameson, Muhammad Faisal, Beth Fylan, Greg C Bristow, Jaspreet Sohal, Caroline Dalton, Gurdeep S Sagoo, Alastair G Cardno, Samantha L McLean

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Adam JamesonBradford District Care NHS Foundation Trust, Bradford, UK.ORCID 0000-0002-3248-2302
Muhammad FaisalWolfson Centre for Applied Health Research, Bradford, UK.
Beth FylanSchool of Pharmacy & Medical Sciences, University of Bradford, Bradford, UK.
Greg C BristowSchool of Pharmacy & Medical Sciences, University of Bradford, Bradford, UK.
Jaspreet SohalBradford District Care NHS Foundation Trust, Bradford, UK.
Caroline DaltonBiomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
Gurdeep S SagooPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Alastair G CardnoLeeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK.
Samantha L McLeanSchool of Pharmacy & Medical Sciences, University of Bradford, Bradford, UK.ORCID 0000-0001-9328-8928
University of Bradford · GBBradford District Care NHS Foundation Trust · GBNewcastle University · GBSheffield Hallam University · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics').

aimsThis study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance.

methodsA cross-sectional study took place extracting data from 243 patients' medical records to explore psychosis drug prescribing, including drug transitions. Demographic data such as age, sex, ethnicity, and clinical sub-team were collected and summarised. Descriptive statistics explored the proportion of 'CYP2D6-PGx antipsychotic' prescribing and the nature of transitions. We used logistic regression analysis to investigate associations between demographic variables and prescription of 'CYP2D6-PGx antipsychotic' versus 'non-CYP2D6-PGx antipsychotic'.

resultsTwo-thirds (164) of patients had been prescribed a 'CYP2D6-PGx antipsychotic' (aripiprazole, risperidone, haloperidol or zuclopenthixol). Over a fifth (23%) of patients would have met the suggested criteria for PGx testing, following two psychosis drug trials. There were no statistically significant differences between age, sex, or ethnicity in the likelihood of being prescribed a 'CYP2D6-PGx antipsychotic'.

conclusionsThis study demonstrated high rates of prescribing 'CYP2D6-PGx-antipsychotics' in an EIP cohort, providing a rationale for further exploration of how PGx testing can be implemented in EIP services to personalise the prescribing of drugs for psychosis.

Indexed as

Antipsychotic AgentsPsychoses, Substance-InducedPsychotic DisordersCross-Sectional StudiesCytochrome P-450 CYP2D6HumansPharmacogeneticsAntipsychotic AgentsCytochrome P-450 CYP2D6AntipsychoticsPersonalised MedicinePharmacogeneticsPharmacogenomicsPsychosisReceptor Antagonist (D2)Receptor Antagonist (D2, 5-HT2)Receptor Antagonist (D2, 5-HT2, NE, alpha-2)Receptor Partial Agonist (D2, 5-HT1A)Schizophrenia

Identifiers

PMID38494658
PMCPMC11010551
OpenAlexW4392922182

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.